Abstract
A number of innovative delivery systems for acute antipsychotic pharmacotherapy have been developed over the years which include
oral suspensions, rapidly dissolving wafers and acute intramuscular preparations. Currently, the availability of first generation
antipsychotic (FGA) formulations is limited to two high potency agents: haloperidol and fluphenazine. At Yale New-Haven Psychiatric
Hospital, the hospital pharmacy was able to create perphenazine suspension, a mid-potency FGA, with a record of effectiveness
and tolerability that was no worse than that of second generation antipsychotics (SGAs) in the CATIE trial. In this study
we compare perphenazine suspension to other first and SGAs in the risk of extrapyramidal reactions and whether or not patients
were continued on the same antipsychotic they were started with at the time of discharge. Medical records of patients who
received acute pharmacotherapy in a unique form while hospitalized at Yale New Haven Psychiatric Hospital from July 2009 to
December 2009 were examined. All data were collected thru a chart review using a form that was created to systematically document
experiences. A total of 229 patients were included in the study. There were no significant differences between treatment groups
on gender, age, race or diagnosis. In the entire samples 1.75% had pseudo-parkonisnism, 1.31% had acute dystonia, 0.04% had
tardive dyskinesia, 1.31% akithesia, and 4.8% any neurological side effects. There were no significant differences between
agents in the likelihood of any of these side effects or of having any side effect. Higher use of anticholinergics was found
in patients treated with FGAs. We also found that 77% were discharged on the same antipsychotic agent they received when they
were initially hospitalized. A wide range of acute oral pharmacoptherapy in non-tablet formulations of first and SGAs should
be available in psychiatric hospital formularies. FGAs seems to be as well tolerated as SGAs.
oral suspensions, rapidly dissolving wafers and acute intramuscular preparations. Currently, the availability of first generation
antipsychotic (FGA) formulations is limited to two high potency agents: haloperidol and fluphenazine. At Yale New-Haven Psychiatric
Hospital, the hospital pharmacy was able to create perphenazine suspension, a mid-potency FGA, with a record of effectiveness
and tolerability that was no worse than that of second generation antipsychotics (SGAs) in the CATIE trial. In this study
we compare perphenazine suspension to other first and SGAs in the risk of extrapyramidal reactions and whether or not patients
were continued on the same antipsychotic they were started with at the time of discharge. Medical records of patients who
received acute pharmacotherapy in a unique form while hospitalized at Yale New Haven Psychiatric Hospital from July 2009 to
December 2009 were examined. All data were collected thru a chart review using a form that was created to systematically document
experiences. A total of 229 patients were included in the study. There were no significant differences between treatment groups
on gender, age, race or diagnosis. In the entire samples 1.75% had pseudo-parkonisnism, 1.31% had acute dystonia, 0.04% had
tardive dyskinesia, 1.31% akithesia, and 4.8% any neurological side effects. There were no significant differences between
agents in the likelihood of any of these side effects or of having any side effect. Higher use of anticholinergics was found
in patients treated with FGAs. We also found that 77% were discharged on the same antipsychotic agent they received when they
were initially hospitalized. A wide range of acute oral pharmacoptherapy in non-tablet formulations of first and SGAs should
be available in psychiatric hospital formularies. FGAs seems to be as well tolerated as SGAs.
- Content Type Journal Article
- Category Original Paper
- Pages 1-7
- DOI 10.1007/s11126-011-9203-1
- Authors
- Pascale Chrisphonte, Department of Psychiatry, Yale University, School of Medicine, 300 George St, Suite 901, New Haven, CT 06511, USA
- Robert B. Ostroff, Clinical Psychiatry, Yale University, New Haven, CT, USA
- Robert A. Rosenheck, VA New England Mental Illness Research and Education Center, 151D, West Haven, CT, USA
- Journal Psychiatric Quarterly
- Online ISSN 1573-6709
- Print ISSN 0033-2720